45 y\u0131ld\u0131r ila\u00e7 sanayine Ar-Ge, \u0130malat, Pazarlama ve Genel M\u00fcd\u00fcrl\u00fck alanlar\u0131nda hizmet ediyorum. Galatasaray Lisesi\u2019nin ard\u0131ndan, Basel \u00dcniversitesi Eczac\u0131l\u0131k Fak\u00fcltesi\u2019nde y\u00fcksek lisans ve doktora e\u011fitimimi tamamlad\u0131m. Ayr\u0131ca zaman i\u00e7erisinde, MBA yapt\u0131m ve IMD, Harvard ve LBS\u2019de e\u011fitimler g\u00f6rd\u00fcm.<\/p>\n\n\n
![\"\"](\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/altan-demirdere-1-1-768x1024.jpg\")
<\/figure><\/div>\n\n\nT\u00fcrkiye, \u0130svi\u00e7re, Macaristan ve Rusya\u2019da de\u011fi\u015fik pozisyonlarda \u00e7al\u0131\u015ft\u0131m. \u0130\u015f hayat\u0131m\u0131n yar\u0131s\u0131 yurt d\u0131\u015f\u0131nda ge\u00e7ti. T\u00fcrkiye\u2019de Ara\u015ft\u0131rmac\u0131 \u0130la\u00e7 Firmalar\u0131 Derne\u011fi\u2019ni (A\u0130FD) kurduk ve 5 d\u00f6nem boyunca Kurucu Y\u00f6netim Kurulu Ba\u015fkanl\u0131\u011f\u0131n\u0131 y\u00fcr\u00fctt\u00fcm.<\/p>\n\n\n\n
45 senenin 42 senesini \u0130svi\u00e7re k\u00f6kenli Sandoz\/Novartis\u2019de de\u011fi\u015fik pozisyonlarda \u00e7al\u0131\u015farak tamamlad\u0131m. 65 ya\u015f\u0131nda ya\u015f haddinden zorunlu emeklili\u011fimden sonra da son 3 y\u0131ld\u0131r da \u0130spanyol k\u00f6kenli Exeltis \u0130la\u00e7\u2019\u0131n ba\u015f\u0131nday\u0131m.<\/p>\n\n\n\n
Uzun y\u0131llard\u0131r global \u00f6l\u00e7ekteki firmalarda genel m\u00fcd\u00fcr olarak g\u00f6rev al\u0131yorsunuz. Bunca y\u0131ll\u0131k tecr\u00fcbenizle de\u011ferlendirdi\u011finizde ge\u00e7mi\u015ften g\u00fcn\u00fcm\u00fcze sekt\u00f6rde sizce en \u00f6nemli de\u011fi\u015fimler hangi noktalarda, ne y\u00f6nde oldu?<\/strong><\/p>\n\n\n\n \u00d6nce ilac\u0131n tarihsel geli\u015fimine bir g\u00f6z atal\u0131m. \u0130nsanlar eski \u00e7a\u011flarda yakaland\u0131klar\u0131 hastal\u0131klardan kurtulmak i\u00e7in bitkilerden ve hayvanlardan yararlanm\u0131\u015flard\u0131r. Yani ilk ila\u00e7lar bitkisel ve hayvansal k\u00f6kenliydi (majistral ila\u00e7lar). 1800\u2019lerin ortalar\u0131nda ila\u00e7 fabrikalar\u0131 kurulmaya ba\u015fland\u0131 ve ila\u00e7 aktif maddeleri laboratuvarlarda sentezlenerek haz\u0131r m\u00fcstahzarlar (ofisinal ila\u00e7lar) olarak eczanelerde sat\u0131lmaya ba\u015fland\u0131. 1950\u2019lerden itibaren ise orijinal ila\u00e7lar\u0131n jenerikleri ve sentezlenmesi laboratuvarlarda \u00e7ok uzun zaman alacak b\u00fcy\u00fck molek\u00fcllerin, bakterilere \u00fcrettirildi\u011fi biyolojik ila\u00e7lar ile tan\u0131\u015ft\u0131k. 2000\u2019lere geldi\u011fimizde de gen replasman tedavisi \u00f6n\u00fcm\u00fcze \u00e7\u0131kt\u0131. Bu son noktada art\u0131k insanlarda kronik hastal\u0131klara yol a\u00e7an gen bozukluklar\u0131n\u0131 giderecek ila\u00e7lar haz\u0131rlan\u0131yor.<\/p>\n\n\n\n Bence global ila\u00e7 sanayi son 65 y\u0131ld\u0131r \u00f6nemli ad\u0131mlar att\u0131 ve atmaya devam ediyor. Ben bu d\u00f6nemin son 45 y\u0131l\u0131nda biyolojik ila\u00e7lar\u0131n, sonras\u0131nda biyobenzer jenerik ila\u00e7lar\u0131n ve gen replasman tedavisinin ke\u015ffine tan\u0131kl\u0131k ettim.<\/p>\n\n\n\n K\u00fcresel ila\u00e7 end\u00fcstrisindeki trendlerle T\u00fcrkiye\u2019deki geli\u015fmeler aras\u0131nda nas\u0131l bir fark ya da paralellik g\u00f6r\u00fcyorsunuz?<\/strong><\/p>\n\n\n Biz T\u00fcrkiye\u2019de ila\u00e7 sanayine 1900\u2019larin ba\u015f\u0131nda kat\u0131ld\u0131k, yani arkadan geldik, ancak 100 senede \u00e7ok yol kat ettik. Bug\u00fcn T\u00fcrkiye\u2019de d\u00fcnya \u00f6l\u00e7e\u011finde jenerik ila\u00e7 \u00fcretimi ve ihracat\u0131 yapan bir\u00e7ok firmam\u0131z var. Ancak maalesef, ila\u00e7 etkin maddesi \u00fcreten firmalar\u0131m\u0131z \u00e7ok az ve ila\u00e7 Ar-Ge\u2019si yapan firmalar\u0131m\u0131z da hen\u00fcz yok. Yani hen\u00fcz T\u00fcrkiye yepyeni bir ila\u00e7 molek\u00fcl\u00fc ke\u015ffederek d\u00fcnya t\u0131bb\u0131n\u0131n hizmetine sunmam\u0131\u015ft\u0131r.<\/p>\n\n\n\n \u0130la\u00e7ta ara\u015ft\u0131rma \u00e7al\u0131\u015fmalar\u0131, yani yeni molek\u00fcllerin ke\u015ffi, 10 seneden fazla bir u\u011fra\u015f gerektiren ve 1.5 milyar dolar\u0131n \u00fczerinde maliyeti olan bir u\u011fra\u015ft\u0131r. Yeni bir molek\u00fcl\u00fc bir tek ki\u015fi de\u011fil, hekim, eczac\u0131, biyolog, kimyager, fizik\u00e7i gibi de\u011fi\u015fik bran\u015flardan olu\u015fan bilim adamlar\u0131 ke\u015ffeder. \u00dclkemizde bu t\u00fcr bilim adamlar\u0131m\u0131z mevcuttur, ancak bunlar\u0131n hemen hepsi yurt d\u0131\u015f\u0131ndaki Ar-Ge merkezlerinde \u00e7al\u0131\u015fmaktad\u0131r. T\u00fcrkiye\u2019miz, 10 sene boyunca toplam 1.5 milyar dolar yat\u0131r\u0131m yapacak ve bundan sonra yat\u0131r\u0131m\u0131n\u0131n kar\u015f\u0131l\u0131\u011f\u0131n\u0131 bekleyecek kadar sab\u0131rl\u0131 bir sermaye yap\u0131s\u0131na al\u0131\u015f\u0131k de\u011fildir. Di\u011fer taraftan, bulunan fikrin korunmas\u0131 ve \u00e7al\u0131nd\u0131\u011f\u0131nda cezaland\u0131r\u0131lmas\u0131 hususunda hukuki altyap\u0131m\u0131z da yeterli de\u011fildir. Yoksa siz 9 sene u\u011fra\u015f\u0131rs\u0131n\u0131z, 10. sene ara\u015ft\u0131rmac\u0131lardan birisi \u00e7al\u0131\u015fmalar\u0131 al\u0131r ve bir ba\u015fkas\u0131na f\u0131s\u0131ldar, b\u00f6ylece 9 senelik u\u011fra\u015f\u0131n\u0131z ve harcad\u0131\u011f\u0131n\u0131z para bir anda elinizin alt\u0131ndan kay\u0131p gider.<\/p>\n\n\n\n Ancak, d\u00fcnyada son zamanlarda art\u0131k yeni molek\u00fclleri karma bilim adamlar\u0131ndan olu\u015fan start-up firmalar ke\u015ffedip belirli bir yere kadar geli\u015ftiriyorlar ve ondan sonra Ar-Ge\u2019 ye devam edip bitmi\u015f ila\u00e7 haline getirmesi i\u00e7in b\u00fcy\u00fck ila\u00e7 firmalar\u0131na \u00e7ok y\u00fcksek mebla\u011flara sat\u0131yorlar. \u00d6rne\u011fin Novartis, bir start-up firman\u0131n kas kayb\u0131na yol a\u00e7an genetik ge\u00e7i\u015fli \u00f6l\u00fcmc\u00fcl SMA hastal\u0131\u011f\u0131 i\u00e7in geli\u015ftirdi\u011fi gen replasman tedavisi ilac\u0131n\u0131 2010\u2019lu y\u0131llar\u0131n sonunda firmadan 9 milyar dolara sat\u0131n ald\u0131.<\/p>\n\n\n\n Bence bu t\u00fcr start-up firmalar\u0131 yurdumuzda kurabilecek ve ara\u015ft\u0131rma yapabilecek beyin g\u00fcc\u00fcne sahibiz. Bu firmalar, d\u00fcnyada oldu\u011fu gibi, ara\u015ft\u0131rmalar\u0131n\u0131 belirli bir seviyeye getirip olumlu sonu\u00e7lar elde ettiklerinde, \u00e7al\u0131\u015fmalar\u0131n\u0131 b\u00fcy\u00fck ila\u00e7 firmalar\u0131na satabilirler. Yeter ki fikrin korunmas\u0131 ve \u00e7al\u0131nd\u0131\u011f\u0131nda cezaland\u0131r\u0131lmas\u0131 hususunda hukuki altyap\u0131m\u0131z kuvvetli olsun.<\/p>\n\n\n\n \u0130la\u00e7 fiyatland\u0131rma politikalar\u0131, ruhsatland\u0131rma s\u00fcre\u00e7leri, kur fark\u0131 ve geri \u00f6deme s\u00fcre\u00e7leri sekt\u00f6r\u00fcn en \u00f6nemli g\u00fcndemleri aras\u0131nda. Bu konuda ya\u015fanan zorluklar\u0131 nas\u0131l de\u011ferlendirirsiniz? D\u00f6viz bazl\u0131 maliyetler ve global tedarik zinciri sorunlar\u0131 T\u00fcrkiye operasyonlar\u0131n\u0131 nas\u0131l etkiliyor?<\/strong><\/p>\n\n\n\n 2000\u2019li y\u0131llar\u0131n ilk \u00e7eyre\u011finde, Bakanl\u0131k ve ila\u00e7 sanayinin beraber \u00e7al\u0131\u015fmas\u0131yla iyi bir ila\u00e7 fiyatland\u0131rma sistemi kuruldu. Bundan \u00f6nce ila\u00e7ta maliyet bazl\u0131 bir fiyatland\u0131rma politikas\u0131 izleniyordu ki, bu durum baz\u0131 firmalar\u0131n maliyetleri \u015fi\u015firmesine ve devletin zarar etmesine neden olabiliyordu. Biz, serbest bir pazar olan Avrupa Birli\u011fi\u2019ndeki en ucuz be\u015f \u00fclkeyi beraberce belirledik ve ilac\u0131m\u0131z bu be\u015f \u00fclkeden en ucuz hangisinde sat\u0131l\u0131yorsa o \u00fclkenin fiyat\u0131n\u0131 referans olarak ald\u0131k. Bunun da \u00fcst\u00fcne SSK hastanelerinin eczanelerinin kapat\u0131laca\u011f\u0131, yaz\u0131lan ila\u00e7lar\u0131n art\u0131k serbest eczaneler \u00fczerinden sat\u0131laca\u011f\u0131 ve pazar\u0131n geni\u015fleyece\u011fi varsay\u0131m\u0131yla %10 iskonto verdik. Euro kuru her %5 artt\u0131\u011f\u0131nda da ertesi ay kur art\u0131\u015f\u0131ndan dolay\u0131 ilaca ayn\u0131 oranda zam verilecekti.<\/p>\n\n\n\n Bu karara bir m\u00fcddet Bakanl\u0131k taraf\u0131ndan uyuldu. Daha sonra giderek, %10 iskonto %40\u2019lara kadar \u00e7\u0131kar\u0131ld\u0131. Daha sonra da kur art\u0131\u015f\u0131na g\u00f6re ilac\u0131n TL fiyat\u0131na y\u0131llarca zam verilmedi, kur donduruldu ve fiyat sabit kald\u0131. Bunu takiben g\u00fcncel kurun %60\u2019\u0131 referans olarak al\u0131nd\u0131 ve ilac\u0131n TL fiyat\u0131 o \u015fekilde hesapland\u0131. \u015eu anda Avrupa\u2019daki en ucuz 5 \u00fclke aras\u0131nda en ucuz ila\u00e7 100 TL iken T\u00fcrkiye\u2019de bu fiyat 20-25 TL\u2019ye d\u00fc\u015fm\u00fc\u015f vaziyette.<\/p>\n\n\n\n Kabaca bak\u0131ld\u0131\u011f\u0131nda, k\u0131sa s\u00fcreli bir tasarruf elde etti\u011fimiz d\u00fc\u015f\u00fcn\u00fclebilir. Ancak holistik bir bak\u0131\u015f a\u00e7\u0131s\u0131yla bence zarar\u0131m\u0131z k\u00e2r\u0131m\u0131zdan \u00e7ok daha fazla olmu\u015ftur. 2008\u2019e kadar olan d\u00f6nemde T\u00fcrk ila\u00e7 sanayi d\u00fcnyada 12. s\u0131radayd\u0131, ancak yap\u0131lan uygulamalar sonucu T\u00fcrkiye\u2019de \u00fcretim avantaj\u0131 kayboldu ve bug\u00fcn itibaryla 21. s\u0131raya geriledik. Birincisi, yabanc\u0131 ila\u00e7 firmalar\u0131 a\u00e7t\u0131klar\u0131 fabrikalar\u0131 tek tek kapat\u0131p, \u00fcretim ve ihracattan, fasonda \u00fcrettirme veya ithal etme durumuna d\u00fc\u015ft\u00fcler. Ayr\u0131ca, bir\u00e7ok yeni ke\u015ffedilen ila\u00e7 da a\u015f\u0131r\u0131 d\u00fc\u015f\u00fck fiyattan dolay\u0131 \u00fclkemize getirilemez oldu. Bunun sonucunda, ila\u00e7 end\u00fcstrisindeki istihdam kayb\u0131 ve ihracat potansiyelinin tam olarak de\u011ferlendirilememesi ba\u015fl\u0131ca zararlar\u0131m\u0131zdand\u0131r.<\/p>\n\n\n\n T\u00fcrkiye\u2019de ila\u00e7 eri\u015fimini art\u0131rmak ve sekt\u00f6r\u00fc s\u00fcrd\u00fcr\u00fclebilir k\u0131lmak i\u00e7in hangi ad\u0131mlar \u00f6ncelikli olmal\u0131?<\/strong><\/p>\n\n\n\n Baz\u0131 ki\u015filerde ilk akla gelen devlet deste\u011fi oluyor. Bu elbette \u00f6nemli, ancak ba\u015far\u0131y\u0131 yaln\u0131zca bu desteklerle sa\u011flaman\u0131n m\u00fcmk\u00fcn oldu\u011funa inanm\u0131yorum. Devletin as\u0131l rol\u00fc; ruhsatland\u0131rma ve fiyatland\u0131rma s\u00fcre\u00e7lerini etkin bi\u00e7imde y\u00fcr\u00fctmesi, patent ve veri koruma d\u00fczenlemelerini tam anlam\u0131yla hayata ge\u00e7irmesi ve b\u00f6ylece ila\u00e7 sanayinin \u00f6n\u00fcn\u00fc a\u00e7mas\u0131d\u0131r. Bu ko\u015fullar sa\u011fland\u0131\u011f\u0131nda, yap\u0131lacak yat\u0131r\u0131m kayna\u011f\u0131 da bir \u015fekilde bulunacakt\u0131r diye d\u00fc\u015f\u00fcn\u00fcyorum.<\/p>\n\n\n\n \u00d6rne\u011fin, 2015 y\u0131l\u0131nda devletimiz \u00fclkemizde patent s\u00fcresi dolmu\u015f pahal\u0131 biyolojik ila\u00e7lar\u0131n jeneriklerinin (biyobenzer ila\u00e7lar) \u00fcretimi i\u00e7in ila\u00e7 firmalar\u0131na maddi destek ve \u00fcretecekleri mallar\u0131n\u0131 al\u0131m garantisini verdi. Bundan yararlanan firmalar, tam \u00fcrettikleri \u00fcr\u00fcnlerine fiyat alacakken, patent s\u00fcresi dolan orijinal \u00fcr\u00fcn\u00fcn firmas\u0131 fiyat\u0131n\u0131 yar\u0131 yar\u0131ya d\u00fc\u015f\u00fcrd\u00fc. Bunu yapabilir, \u00e7\u00fcnk\u00fc zaten patent s\u00fcresi boyunca kazanaca\u011f\u0131n\u0131 kazanm\u0131\u015f ve k\u00e2r marj\u0131 da y\u00fcksek, \u00e7\u00fcnk\u00fc t\u00fcm d\u00fcnya i\u00e7in b\u00fcy\u00fck \u00f6l\u00e7eklerde \u00fcretiyor. Bunun \u00fczerine SGK da te\u015fvik verilen yerli firmadan ayn\u0131 fiyata inmesini istedi ama b\u00f6yle bir durumda, ilac\u0131 daha yeni ve sadece T\u00fcrkiye i\u00e7in \u00fcretmeye ba\u015flayan yerli firma kesin zarar ederdi. Dolay\u0131s\u0131yla yerli \u00fcr\u00fcnlerin bir\u00e7o\u011fu do\u011fmadan \u00f6ld\u00fc ve devlet verdi\u011fi te\u015fvik paras\u0131n\u0131, firma da onun \u00fcst\u00fcne yapt\u0131\u011f\u0131 yat\u0131r\u0131m\u0131 kaybetti.<\/p>\n\n\n\n Bunun nedeni bence Bakanl\u0131klar\u0131m\u0131z aras\u0131nda koordinasyon olmamas\u0131. Fiyatland\u0131rma konusunda en ucuz ila\u00e7 k\u0131stas olarak al\u0131n\u0131yor. Oysaki \u00fclkede \u00fcretim yapan, istihdam sa\u011flayan ve ihracat yapan firmalar\u0131n faaliyetlerinin bir paket \u015feklinde de\u011ferlendirilmesi gerekir diye d\u00fc\u015f\u00fcn\u00fcyorum. Bu konuda ilgililerle konu\u015fuldu\u011fu zaman \u00fcretim, istihdam ve ihracat gibi konular\u0131n ba\u015fka bakanl\u0131klar\u0131n sorumlulu\u011fu oldu\u011funu ifade ediyorlar. Dolay\u0131s\u0131 ile en ucuza ila\u00e7 veren firmalar kazanabiliyor ama T\u00fcrkiye\u2019ye imalat, ihracat a\u00e7\u0131s\u0131ndan katk\u0131s\u0131 olan firmalar kaybedebiliyorlar.<\/p>\n\n\n\n T\u00fcrkiye\u2019de Ar-Ge yapman\u0131n \u00f6n\u00fcndeki en \u00f6nemli engeller sizce neler? Devletin sundu\u011fu te\u015fvik ve destek programlar\u0131 yeterli mi? Mevcut sistemde iyile\u015ftirilmesi gereken noktalar sizce neler?<\/strong><\/p>\n\n\n\n D\u00fcnyada ila\u00e7 sanayii, cirosunun %17 kadar b\u00fcy\u00fck bir oran\u0131n\u0131 Ar-Ge \u00e7al\u0131\u015fmalar\u0131na ay\u0131r\u0131yor. Bu \u00e7ok b\u00fcy\u00fck bir rakam. Bu alanda t\u00fcm sanayilerin d\u00fcnya ortalamas\u0131 %5 civar\u0131ndad\u0131r.<\/p>\n\n\n\n Dolay\u0131s\u0131 ile birinci \u015fart, \u00fclkede k\u00e2rl\u0131 bir ila\u00e7 sanayinin olmas\u0131n\u0131 sa\u011flamak ve bu k\u00e2r\u0131n \u00f6nemli bir k\u0131sm\u0131n\u0131n Ar-Ge yat\u0131r\u0131mlar\u0131 ve ihracata y\u00f6nlendirilip y\u00f6nlendirilmedi\u011fini yak\u0131ndan takip etmektir. Bunun i\u00e7in de fiyatland\u0131rma ve ruhsatland\u0131rma s\u00fcre\u00e7leri \u015feffaf bir bi\u00e7imde y\u00fcr\u00fct\u00fclmeli, patent ve veri koruma d\u00fczenlemeleri ve s\u00fcre\u00e7leri de tam anlam\u0131yla hayata ge\u00e7irilerek, ila\u00e7 sanayinin \u00f6n\u00fc a\u00e7\u0131lmal\u0131d\u0131r.<\/p>\n\n\n\n Asl\u0131nda bu i\u015f bu kadar basittir. Sa\u011fl\u0131k ve ila\u00e7 harcamalar\u0131na bir masraf de\u011fil, yat\u0131r\u0131m olarak bakmak gerekir. Hem \u00fclke insan\u0131na hem de \u00fclke ekonomisine yat\u0131r\u0131m!<\/p>\n\n\n\n Almanya\u2019da bir enstit\u00fcn\u00fcn d\u00fcnya \u00e7ap\u0131nda yapt\u0131\u011f\u0131 bir ara\u015ft\u0131rmaya g\u00f6re, bir \u00fclke ila\u00e7 ve sa\u011fl\u0131k harcamalar\u0131na GSY\u0130H\u2019sinden ne kadar pay ay\u0131r\u0131yorsa, ila\u00e7 ve sa\u011fl\u0131k end\u00fcstrisinin \u00fclke ekonomisine getirdi\u011fi katk\u0131 pay\u0131 da ayn\u0131 oranda art\u0131yor. Yani ila\u00e7 ve sa\u011fl\u0131k harcamalar\u0131 bir m\u00fcddet sonra kendi kendini s\u00fcbvanse ediyor. Yeter ki buna inan\u0131ls\u0131n ve bir m\u00fcddet kararl\u0131l\u0131kla sabredilsin.<\/p>\n\n\n\n Klinik ara\u015ft\u0131rmalar konusunda da asl\u0131nda \u00fclke olarak b\u00fcy\u00fck bir potansiyelimiz olmas\u0131na ra\u011fmen ald\u0131\u011f\u0131m\u0131z pay olduk\u00e7a d\u00fc\u015f\u00fck, bu konuda ne d\u00fc\u015f\u00fcn\u00fcyorsunuz, bu pay\u0131 art\u0131rmak \u00fczere neler yap\u0131labilir?<\/strong><\/p>\n\n\n\n Sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fclerde ve hastalarda yap\u0131lan klinik ara\u015ft\u0131rmalar, yeni bir ilac\u0131n t\u00fcm Ar-Ge masraf\u0131n\u0131n \u00f6nemli k\u0131sm\u0131n\u0131 olu\u015fturur. T\u00fcm geli\u015fmi\u015f \u00fclkeler, klinik ara\u015ft\u0131rmalar\u0131n en b\u00fcy\u00fck talibidir. D\u00fcnyada y\u0131lda 100 milyar dolarl\u0131k ila\u00e7 klinik ara\u015ft\u0131rmas\u0131 yap\u0131lmakta olup, bunun 1\/3\u2019\u00fc Avrupa\u2019da, 2\/3\u2019\u00fc ise ABD ve Japonya\u2019dad\u0131r. Avrupa\u2019daki 33 milyar dolarl\u0131k ara\u015ft\u0131rman\u0131n 2\/3 \u2018\u00fcne ise \u0130svi\u00e7re, Almanya, \u0130ngiltere ve Fransa talip olmu\u015ftur. \u00dclkemiz 1990\u2019lar\u0131n sonundan itibaren bu y\u00f6nde \u00f6nemli ad\u0131mlar atm\u0131\u015ft\u0131r, ancak yine de 33 milyar dolardaki pay\u0131 \u00e7ok d\u00fc\u015f\u00fckt\u00fcr, her y\u0131l artmaktad\u0131r ancak \u00e7ok daha fazla artabilir.<\/p>\n\n\n\n T\u00fcrkiye\u2019de ila\u00e7 sekt\u00f6r\u00fcnde s\u00fcrd\u00fcr\u00fclebilir b\u00fcy\u00fcme i\u00e7in kamu-\u00f6zel sekt\u00f6r i\u015f birli\u011finde ne gibi ad\u0131mlar at\u0131lmal\u0131?<\/strong><\/p>\n\n\n\n Takdir edilmelidir ki, ila\u00e7ta i\u00e7inde bulundu\u011fumuz durum s\u00fcrd\u00fcr\u00fclebilir de\u011fildir. Kayserilinin e\u015fe\u011fini y\u00fckleyip, y\u00fckleyip, \u201cTam al\u0131\u015f\u0131yordu, \u00f6ld\u00fc\u201d demesi misali, sanki ila\u00e7 sanayinin k\u0131r\u0131lma noktas\u0131 test edilmeye \u00e7al\u0131\u015f\u0131lmaktad\u0131r. Ayr\u0131ca, 100 y\u0131ll\u0131k yerli ila\u00e7 sanayicileri yan\u0131nda, 4 duvar yap\u0131p 2 makina alan ucuz ila\u00e7 \u00fcreticileri t\u00fcremi\u015ftir. Makinan\u0131z Rolls-Royce bile olsa, e\u011fer bunu kamyon \u015fof\u00f6r\u00fc mantalitesi ile kullan\u0131yorsan\u0131z, kalitede d\u00fcnya standartlar\u0131n\u0131 asla yakalayamazs\u0131n\u0131z.<\/p>\n\n\n\n Bilinmesi gereken, bir \u00fclkede kaliteli ila\u00e7 sanayi \u00f6l\u00fcrse, yeniden do\u011fmas\u0131n\u0131n \u00e7ok zor oldu\u011fudur. Rusya bunun en g\u00fczel \u00f6rne\u011fidir. SSCB zaman\u0131nda ila\u00e7 end\u00fcstrisini Slovenya, Macaristan, Polonya ve \u00c7ek Cumhuriyeti\u2019ne havale etmi\u015f, kendisi silah ve uzay end\u00fcstrisine odaklanm\u0131\u015ft\u0131r. Bu sebeple, 1990\u2019lardan bu yana kendi yerli ila\u00e7 end\u00fcstrisini h\u00e2l\u00e2 do\u011fru d\u00fczg\u00fcn kuramam\u0131\u015ft\u0131r.<\/p>\n\n\n\n Bence devletimizin bize verece\u011fi en b\u00fcy\u00fck te\u015fvik ve destek, yukar\u0131da belirtti\u011fim \u015fartlar\u0131n yerine getirilmesi ile olacakt\u0131r. Bunu takiben de inan\u0131yorum ki su, yolunu bulacakt\u0131r.<\/p>\n\n\n\n Son olarak ila\u00e7 sekt\u00f6r\u00fcnde \u00e7al\u0131\u015fan gen\u00e7lere ba\u015far\u0131l\u0131 bir kariyer in\u015fa etmeleri i\u00e7in \u00f6nerileriniz ne olur?<\/strong><\/p>\n\n\n\n Ba\u015far\u0131l\u0131 bir kariyer in\u015fa etmek ciddi bir emek ve kararl\u0131l\u0131k gerektirir. \u0130\u015f -\u00f6zel ya\u015fam dengesini, \u201cSaat 17.00\u2019de mesaim biter, bundan sonras\u0131 bana ait\u201d anlay\u0131\u015f\u0131yla kurmaya \u00e7al\u0131\u015fanlar, ne yaz\u0131k ki \u00e7o\u011fu zaman alt\u0131 ay bir firmada, bir y\u0131l ba\u015fka bir firmada savrulan bir kariyer \u00e7izgisine mahk\u00fbm oluyor. \u0130yi bir kariyerin mutlaka bir bedeli vard\u0131r. Elbette \u00f6zel ya\u015fam \u00e7ok k\u0131ymetlidir; ancak burada belirleyici olan harcanan zaman\u0131n miktar\u0131 de\u011fil, niteli\u011fidir. Zaman\u0131 do\u011fru y\u00f6netebilenler i\u00e7in i\u015f ve \u00f6zel ya\u015fam dengesini sa\u011flamak m\u00fcmk\u00fcnd\u00fcr.<\/p>\n","protected":false},"excerpt":{"rendered":" \u0130la\u00e7 sekt\u00f6r\u00fcnde 45 y\u0131l\u0131 a\u015fan uluslararas\u0131 tecr\u00fcbeye sahip, Exeltis T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc Dr. Ecz. Altan Demirdere ile ila\u00e7 sanayinin ge\u00e7mi\u015ften bug\u00fcne evrimini, ila\u00e7 fiyatland\u0131rma politikalar\u0131n\u0131n sekt\u00f6re etkisini, T\u00fcrkiye\u2019nin Ar-Ge potansiyelini ve s\u00fcrd\u00fcr\u00fclebilir bir sekt\u00f6r i\u00e7in at\u0131lmas\u0131 gereken temel ad\u0131mlar\u0131 konu\u015ftuk.<\/p>\n","protected":false},"author":1,"featured_media":4558,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,2],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4553"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4553"}],"version-history":[{"count":3,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4553\/revisions"}],"predecessor-version":[{"id":4564,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4553\/revisions\/4564"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/4558"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/altan-demirdere-2-768x1024.jpg\")
<\/figure><\/div>\n\n\n